The current limitations of molecular diagnostics, such as PCR, do not allow for rapid screening and personalized follow-up of cancers and viral diseases. Healthcare professionals and institutions are therefore looking for simple, rapid and cost-effective tests for screening and monitoring patients.
BrightSens Diagnostics will provide the solution to these needs by offering highly sensitive Point of Care tests. Our patented technology, with unique properties, is the result of 10 years of research supported by 2 ERC contracts with over 2M Euros.
Our ultra-bright and ultra-sensitive fluorescent NanoAntennas amplify a detection signal. They allow direct measurement of very low concentrations of RNA - disease biomarkers - without enzymes, by simple fluorescence measurement. Our Point of Care tests will revolutionize molecular diagnostics.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 11 Rue De L'académie, Strasbourg,67000,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://brightsens-diag.com/
- HQ
- Strasbourg
Brightsens Diagnostics Questions
Brightsens Diagnostics's website is https://brightsens-diag.com/
Brightsens Diagnostics's LinkedIn profile is https://fr.linkedin.com/company/brightsens-diagnostics
Brightsens Diagnostics has
7 employees.
View email and phone details for 7
employees at Brightsens Diagnostics.
Brightsens Diagnostics's industry is
Biotechnology Research
Brightsens Diagnostics's top competitors are
Arkeale,
Serendip Innovations,
Astranice,
Visible Patient Lab,
Occentis,
Biosynex Pharma,
Superbranche,
Biper Therapeutics,
Eifhytec,
Spartha Medical.
Brightsens Diagnostics's categories are Biotechnology Research
Brightsens Diagnostics's founding year is 2022
